AWM
ADMA icon

Abound Wealth Management’s ADMA Biologics ADMA Stock Holding History

Abound Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84 Hold
10
– – ﹤0.01% 1313
2026
Q1 		$91 Hold
10
– – ﹤0.01% 1430
2025
Q4 		$183 Hold
10
– – ﹤0.01% 1211
2025
Q3 		$147 Hold
10
– – ﹤0.01% 1229
2025
Q2 		$183 Sell
10
-5
-33% -$102 ﹤0.01% 1067
2025
Q1 		$298 Sell
15
-1
-6% -$17 ﹤0.01% 872
2024
Q4 		$275 Hold
16
– – ﹤0.01% 920
2024
Q3 		$320 Buy
+16
New +$249 ﹤0.01% 964

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Abound Wealth Management's ADMA Position: Q2 2026 in Review

Abound Wealth Management held its ADMA Biologics (ADMA) position steady in Q2 2026 at 10 shares worth $84. The position accounts for ﹤0.01% of the portfolio, ranked #1313.

Abound Wealth Management first reported a position in ADMA in Q3 2024 and has held it in 8 quarters since. The position peaked at $320 in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Abound Wealth Management held 10 shares of ADMA Biologics worth $84 as of Q2 2026.
  • Abound Wealth Management left its ADMA Biologics share count unchanged in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1313 holding.
  • Abound Wealth Management first reported a position in ADMA Biologics in Q3 2024 and has held it in 8 quarters since.
  • Abound Wealth Management's ADMA Biologics position peaked at $320 in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.